
Press Releases
2025-05 : tiakis Biotech AG Announces Appointment of ex-Actelion Executive Christoph Schmidt as New Supervisory Board Member
2025-04 : tiakis Biotech AG Participates in KOL webcast on Pulmonary Arterial Hypertension (PAH)
2025-01 : tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
2024-12 : tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
2023-06 : First Patient Dosed in Phase Ib/II Trial Evaluating Tiprelestat for Treatment of COVID-19
2023-05 : Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
2022-09 : Proteo Biotech AG becomes tiakis Biotech AG.
2022-06 : Move to a new and larger office in Kiel, Germany.
2022-01 : tiakis Biotech AG has partnered with Northway Biotech to scale up its production capabilities.
2021-12 : German Federal Ministry of Education and Research („BMBF“) selects tiakis Biotech AG to develop Tiprelestat as a potential therapeutic for COVID-19.
2021-10 : New anchor investor Elevat3 Capital joins tiakis Biotech AG.
We will gladly answer your questions.
Get in Contact
phone: +49 431 8888 462
email: info@tiakis.bio